Positron Emission Tomography Market

Positron Emission Tomography Market by Product (Standalone PET Systems, PET/CT Systems, PET/MRI Systems), Application (Oncology, Cardiology, Neurology), End User (Hospitals & Surgical Centers, Diagnostic & Imaging Clinics) & Region - Global Forecasts to 2028

Report Code: MD 8683 Jun, 2023, by marketsandmarkets.com

The global positron emission tomography market in terms of revenue was estimated to be worth $2.5 billion in 2023 and is poised to reach $3.5 billion by 2028, growing at a CAGR of 6.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The increasing number of research grants, rising prevalence of chronic diseases, and rising focus on precision medicine are expected to drive the market during the forecast period.

Global Positron Emission Tomography Market

Positron Emission Tomography Market

To know about the assumptions considered for the study, Request for Free Sample Report

Positron Emission Tomography Market

Positron Emission Tomography Market Dynamics

Driver: Growing adoption of multimodal PET imaging devices

An emerging trend in the diagnostic imaging industry is the use of hybrid imaging modalities in the field of nuclear imaging. The integration of PET/CT machines has significantly improved imaging capabilities and the diagnosis of cancer. The introduction of a high-precision, low-radiation dose PET/CT machine with strong prognostic power based on value has led to a surge in the uptake of PET/CT equipment by hospitals and diagnostic centers.

For example, in October 2020, Siemens Healthineers launched the Biograph Vision Quadra, a new PET/CT scanner with a 106-cm axial PET field of view (FOV). Biograph Vision Quadra facilitates whole-body imaging from the top of the head to the thigh concurrently. The system is intended for both clinical and research purposes, with a particular emphasis on translational research that leverages scientific discoveries to create novel therapies and techniques.

In November 2021, Minfound Medical System Co., Ltd officially launched MinFound high-end ScintCare TOF PET/CT in Hangzhou, China.

Restraint: High Capital and operational costs

The high cost of purchasing and operating PET scanners can limit their availability and use in healthcare settings. The initial capital costs of PET scanners are expensive, ranging from several hundred thousand to over a million dollars, which can be a significant barrier for hospitals and medical centers with limited budgets. Moreover, PET scanners require ongoing maintenance, calibration, and repair, as well as specialized personnel to operate and interpret the results, leading to additional ongoing costs that can be significant and accumulate over time. These factors make PET scanners a costly investment for many healthcare providers. The high cost of PET scanners can make it difficult for smaller hospitals and medical centers in rural areas to purchase and operate these devices. As a result, patients in these areas may have limited access to PET scans, which can lead to delayed diagnosis and treatment.

According to national service and technology review advisory committee, the cost of capital investment for this option is projected to be more than USD 13 million, while the estimated annual operating expenses are expected to range from USD 2 to USD 3 million.

Opportunity: Increase in PET utilization for the detection of breast cancer

The use of PET scanners for breast cancer is an area of increasing opportunity, as PET imaging can provide valuable information about the extent of disease and treatment response. In breast cancer patients, PET scans can be used to evaluate the extent of the disease and the involvement of lymph nodes, as well as to detect metastases to other organs. In addition, PET scanning can be used to monitor treatment response and to detect recurrent disease. This is particularly important in patients who have undergone neoadjuvant chemotherapy, as PET scanning can help to determine the effectiveness of the treatment and guide further management decisions. The use of PET scanning in breast cancer has been shown to improve the accuracy of staging and to impact treatment decisions in a significant proportion of patients.

A systematic review and meta-analysis published in the journal Cancer Imaging in 2020 evaluated the use of PET scanning in the diagnosis and staging of breast cancer. The analysis found that PET scanning had high diagnostic accuracy for detecting both primary breast tumors and metastatic disease and was particularly useful in detecting bone and distant organ metastases.

As breast cancer incidence continues to rise globally, PET scanners have become an important tool for diagnosis and staging of the disease. PET scanning can help determine the extent and spread of cancer, which can inform treatment decisions and improve outcomes for patients. According to the world health organization in the year 2020, around 2.3 million women were diagnosed with breast cancer, resulting in approximately 685,000 deaths globally.

Challenge: Availability of alternate imaging technologies

While PET scanners are powerful diagnostic tools, they are not the only option available. Other imaging technologies, such as MRI and CT scans, can also provide valuable diagnostic information and may be more widely available and affordable. While PET scanning offers unique advantages, such as its ability to detect metabolic activity in tissues, it may not always be the most appropriate or cost-effective option for every patient. The availability of these alternate imaging technologies means that healthcare providers may need to carefully consider the best imaging modality for each individual patient, taking into account factors such as the patient's age, overall health, and the stage of their cancer.

By product, the spectroscopy segment of the positron emission tomography market accounted for the largest share in 2022

Based on product, the global market is segmented into standalone PET systems, PET/CT systems, and PET/MRI systems. In 2022, the PET/CT system segment accounted for the largest market share. The rising use of advanced instruments in oncology research and the need for better turnaround time and enhanced precision is driving the segment growth.

By end user, the hospitals and surgical centers companies segment accounted for the largest share of the positron emission tomography market in 2022

Based on end user, the global market is segmented into hospitals and surgical centers, diagnostic and imaging clinics, ambulatory surgical centers, and other end users. In 2022, hospitals and surgical centers accounted for the largest market share. The highest share of this segment is attributed to prevailing cases of chronic diseases and increased healthcare investments.

By application, the oncology applications segment of the positron emission tomography market to register significant growth in the near future

Based on application, the global market is segmented into oncology, cardiovascular, neurology, and other applications. Oncology applications register the highest growth rate during the forecast period. The major factors responsible for the highest growth rate of this segment are the advanced modalities and increasing cancer cases.

By region, North America is expected to be the largest region of the global positron emission tomography market during the forecast period

North America, comprising the US and Canada, accounted for the largest market share in 2022. Factors such as growing funding for oncology studies, increasing applications in the healthcare/medical sector, and the presence of major players in the region are driving market growth in North America.

Positron Emission Tomography Market by Region

To know about the assumptions considered for the study, download the pdf brochure

As of 2021, prominent players in the market are GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherland), Canon Inc. (Japan), Shanghai United Imaging Healthcare Co., Ltd (China), and Shimadzu Corporation (Japan).

Positron Emission Tomography Market Report Scope

Report Metric

Details

Market Revenue in 2023

$2.5 billion

Projected Revenue by 2028

$3.5 billion

Revenue Rate

Poised to grow at a CAGR of 6.6%

Market Driver

Growing adoption of multimodal PET imaging devices

Market Opportunity

Increase in PET utilization for the detection of breast cancer

This report categorizes the global positron emission tomography market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • PET/CT Systems
    • Low Slice Scanners
    • Medium Slice Scanners
    • High Slice Scanners
  • PET/MRI Systems

By Application

  • Oncology Applications
  • Neurological Applications
  • Cardiovascular Applications
  • Other Applications

By End User

  • Hospital & Surgical Centers
  • Diagnostic & Imaging Clinics
  • Ambulatory Care Centers
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments

  • In May 2021, Zionexa, a top innovator in in-vivo biomarkers for oncology and neurology, has been acquired by GE Healthcare. This acquisition will enable GE Healthcare to advance Zionexa's pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18). Cerianna can be used in conjunction with biopsy to detect estrogen receptor (ER) positive lesions, providing valuable information for treatment selection in patients with recurrent or metastatic breast cancer. The aim is to bring these biomarkers to market and promote more personalized healthcare.
  • In February 2023, United Imaging, a renowned global leader in advanced medical imaging and radiotherapy equipment, participated as a Platinum partner at Arab Health 2023 held in Dubai, UAE from January 30 to February 2. They showcased an extensive range of cutting-edge medical imaging devices including the HD TOF PET/MR uPMR 790, which is capable of producing high-quality images; the uCT 960+, a 16cm detector/640 slice CT scanner that is the fastest cardiac CT scanner in the world; the uMI 780, an ultra-fast high-resolution digital PET/CT scanner; the uMR 680, a 1.5T Wide Bore MRI System with "3T-like" performance, powered by uAiFI; and the uDR 380i Pro, the most compact mobile DR system.
  • In May 2022, Mediso Ltd has recently acquired Bartec Technologies Ltd, a UK-based company that specializes in providing and supporting Nuclear Medicine and Molecular Imaging equipment and accessories.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 23)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKETS COVERED 
           1.3.1 MARKET SEGMENTATION
           1.3.2 GEOGRAPHIC SEGMENTATION
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
    1.6 LIMITATIONS 
    1.7 STAKEHOLDERS 
 
2 RESEARCH METHODOLOGY (Page No. - 27)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Primary sources
                    2.1.2.2 Key industry insights
                    2.1.2.3 Breakdown of primaries
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 RECESSION IMPACT 
    2.3 MARKET SIZE ESTIMATION 
          FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 5 MARKET SIZE ESTIMATION FOR PET SYSTEMS: APPROACH 1 (COMPANY REVENUE ESTIMATION)
                                FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF GE HEALTHCARE
                    2.3.1.2 Approach 2: Customer-based market estimation
                                FIGURE 7 POSITRON EMISSION TOMOGRAPHY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
                    2.3.1.3 CAGR projection
                                FIGURE 8 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
    2.4 DATA VALIDATION APPROACH 
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ASSESSMENT 
    2.6 STUDY ASSUMPTIONS 
    2.7 RISK ASSESSMENT 
           2.7.1 POSITRON EMISSION TOMOGRAPHY MARKET: RISK ASSESSMENT
    2.8 GROWTH RATE ASSUMPTIONS 
 
3 EXECUTIVE SUMMARY (Page No. - 41)
    FIGURE 10 POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT: POSITRON EMISSION TOMOGRAPHY MARKET
 
4 PREMIUM INSIGHTS (Page No. - 44)
    4.1 POSITRON EMISSION TOMOGRAPHY MARKET OVERVIEW 
          FIGURE 14 RISING PREVALENCE OF TARGET DISEASES TO DRIVE GROWTH
    4.2 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT (USD MILLION) 
          FIGURE 15 PET/CT SYSTEMS SEGMENT TO DOMINATE NORTH AMERICAN MARKET DURING FORECAST PERIOD
    4.3 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER (USD MILLION) 
          FIGURE 16 HOSPITALS AND SURGICAL CENTERS FORM LARGEST END-USER SEGMENT IN ASIA PACIFIC MARKET
    4.4 GLOBAL PET/CT SYSTEMS MARKET, BY TYPE 
          FIGURE 17 LOW-SLICE SCANNERS SEGMENT TO HOLD LARGEST SHARE DURING FORECAST PERIOD
    4.5 GEOGRAPHIC SNAPSHOT OF POSITRON EMISSION TOMOGRAPHY MARKET 
          FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 47)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 POSITRON EMISSION TOMOGRAPHY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising target patient population
                                FIGURE 20 NUMBER OF PET PROCEDURES, BY COUNTRY, 2019 VS. 2022
                    5.2.1.2 Growing adoption of multimodal PET imaging devices
                    5.2.1.3 Technological advancements in radiopharmaceuticals and PET systems
                    5.2.1.4 Increasing investments, funds, and grants by public-private organizations
           5.2.2 RESTRAINTS
                    5.2.2.1 High capital and operational costs
                    5.2.2.2 Unfavorable regulatory guidelines
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Improving healthcare infrastructure across emerging economies
                    5.2.3.2 Increasing use of PET in breast cancer detection
                    5.2.3.3 Promising product pipeline
           5.2.4 CHALLENGES
                    5.2.4.1 Availability of alternate imaging technologies
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 1 POSITRON EMISSION TOMOGRAPHY MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 VALUE CHAIN ANALYSIS 
           5.4.1 RESEARCH & DEVELOPMENT
           5.4.2 PROCUREMENT AND PRODUCT DEVELOPMENT
           5.4.3 MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES
                    FIGURE 21 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
    5.5 SUPPLY CHAIN ANALYSIS 
           5.5.1 PROMINENT COMPANIES
           5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES
           5.5.3 END USERS
                    TABLE 2 SUPPLY CHAIN ECOSYSTEM
                    FIGURE 22 SUPPLY CHAIN ANALYSIS
    5.6 ECOSYSTEM COVERAGE 
    5.7 PATENT ANALYSIS 
          FIGURE 23 PATENT DETAILS FOR POSITRON EMISSION TOMOGRAPHY (JANUARY 2013–APRIL 2023)
          FIGURE 24 PATENT DETAILS FOR PET/CT SYSTEMS (JANUARY 2013–APRIL 2023)
          FIGURE 25 PATENT DETAILS FOR PET/MRI SYSTEMS (JANUARY 2013–APRIL 2023)
    5.8 TRADE ANALYSIS 
           5.8.1 TRADE ANALYSIS: POSITRON EMISSION TOMOGRAPHY MARKET
                    TABLE 3 IMPORT DATA FOR POSITRON EMISSION TOMOGRAPHY (HS CODE 902212), BY COUNTRY, 2018–2022 (USD)
                    TABLE 4 EXPORT DATA FOR POSITRON EMISSION TOMOGRAPHY (HS CODE 902212), BY COUNTRY, 2018–2022 (USD)
    5.9 KEY CONFERENCES AND EVENTS (2023–2025) 
          TABLE 5 POSITRON EMISSION TOMOGRAPHY MARKET: LIST OF MAJOR CONFERENCES AND EVENTS
    5.10 TECHNOLOGY ANALYSIS 
    5.11 CASE STUDIES 
           5.11.1 TECHNOLOGICAL CHALLENGES
                     TABLE 6 CASE STUDY 1: DEVELOPING AND IMPROVING MEDICAL IMAGING TECHNOLOGIES
           5.11.2 LOWERING DEPENDENCE ON CONTRACT MANUFACTURING
                     TABLE 7 CASE STUDY 2: DEPENDENCE ON CONTRACT MANUFACTURING AND OUTSOURCING
    5.12 PRICING ANALYSIS 
          TABLE 8 REGION-WISE PRICE RANGE FOR PET SYSTEMS
    5.13 REGULATORY ANALYSIS 
           5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.13.1.1 North America
                    5.13.1.2 Europe
                    5.13.1.3 Asia

6 POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT (Page No. - 66)
    6.1 INTRODUCTION 
          TABLE 10 POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
          TABLE 11 POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (UNITS)
    6.2 STANDALONE PET SYSTEMS 
           6.2.1 FEWER TECHNOLOGICAL ADVANCEMENTS TO AFFECT MARKET GROWTH
                    TABLE 12 STANDALONE PET SYSTEMS MARKET, BY REGION, 2020–2028 (USD MILLION)
                    TABLE 13 STANDALONE PET SYSTEMS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
                    TABLE 14 STANDALONE PET SYSTEMS MARKET, BY END USER, 2020–2028 (USD MILLION)
    6.3 PET/CT SYSTEMS 
          TABLE 15 PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
          TABLE 16 PET/CT SYSTEMS MARKET, BY REGION, 2020–2028 (USD MILLION)
          TABLE 17 PET/CT SYSTEMS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
          TABLE 18 PET/CT SYSTEMS MARKET, BY END USER, 2020–2028 (USD MILLION)
           6.3.1 LOW-SLICE SCANNERS
                    6.3.1.1 Smaller size and lower cost of scanners to drive growth
                                TABLE 19 PET/CT SYSTEMS MARKET FOR LOW-SLICE SCANNERS, BY REGION, 2020–2028 (USD MILLION)
                                TABLE 20 PET/CT SYSTEMS MARKET FOR LOW-SLICE SCANNERS, BY APPLICATION, 2020–2028 (USD MILLION)
                                TABLE 21 PET/CT SYSTEMS MARKET FOR LOW-SLICE SCANNERS, BY END USER, 2020–2028 (USD MILLION)
           6.3.2 MEDIUM-SLICE SCANNERS
                    6.3.2.1 Better picture resolution to propel growth
                                TABLE 22 PET/CT SYSTEMS MARKET FOR MEDIUM-SLICE SCANNERS, BY REGION, 2020–2028 (USD MILLION)
                                TABLE 23 PET/CT SYSTEMS MARKET FOR MEDIUM-SLICE SCANNERS, BY APPLICATION, 2020–2028 (USD MILLION)
                                TABLE 24 PET/CT SYSTEMS MARKET FOR MEDIUM-SLICE SCANNERS, BY END USER, 2020–2028 (USD MILLION)
           6.3.3 HIGH-SLICE SCANNERS
                    6.3.3.1 Increased patient throughput to boost growth
                                TABLE 25 PET/CT SYSTEMS MARKET FOR HIGH-SLICE SCANNERS, BY REGION, 2020–2028 (USD MILLION)
                                TABLE 26 PET/CT SYSTEMS MARKET FOR HIGH-SLICE SCANNERS, BY APPLICATION, 2020–2028 (USD MILLION)
                                TABLE 27 PET/CT SYSTEMS MARKET FOR HIGH-SLICE SCANNERS, BY END USER, 2020–2028 (USD MILLION)
    6.4 PET/MRI SYSTEMS 
           6.4.1 INCREASING NUMBER OF INSTALLED SYSTEMS TO PROPEL GROWTH
                    TABLE 28 PET/MRI SYSTEMS MARKET, BY REGION, 2020–2028 (USD MILLION)
                    TABLE 29 PET/MRI SYSTEMS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
                    TABLE 30 PET/MRI SYSTEMS MARKET, BY END USER, 2020–2028 (USD MILLION)
 
7 POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION (Page No. - 80)
    7.1 INTRODUCTION 
          TABLE 31 POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
    7.2 ONCOLOGY APPLICATIONS 
           7.2.1 LAUNCH OF ADVANCED PET SCANNERS FOR DIAGNOSING AND TREATING CANCER TO DRIVE GROWTH
                    TABLE 32 POSITRON EMISSION TOMOGRAPHY MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
    7.3 NEUROLOGICAL APPLICATIONS 
           7.3.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE GROWTH
                    TABLE 33 POSITRON EMISSION TOMOGRAPHY MARKET FOR NEUROLOGICAL APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
    7.4 CARDIOVASCULAR APPLICATIONS 
           7.4.1 INCREASING GERIATRIC POPULATION TO DRIVE GROWTH
                    TABLE 34 POSITRON EMISSION TOMOGRAPHY MARKET FOR CARDIOVASCULAR APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
    7.5 OTHER APPLICATIONS 
          TABLE 35 POSITRON EMISSION TOMOGRAPHY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
 
8 POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER (Page No. - 86)
    8.1 INTRODUCTION 
          TABLE 36 POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION)
    8.2 HOSPITALS AND SURGICAL CENTERS 
           8.2.1 MODALITY INTEGRATION ADVANTAGES TO DRIVE GROWTH
                    TABLE 37 POSITRON EMISSION TOMOGRAPHY MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2020–2028 (USD MILLION)
    8.3 DIAGNOSTIC AND IMAGING CLINICS 
           8.3.1 GROWING GERIATRIC POPULATION AND CLINICAL VOLUMES TO SUPPORT MARKET GROWTH
                    TABLE 38 POSITRON EMISSION TOMOGRAPHY MARKET FOR DIAGNOSTIC AND IMAGING CLINICS, BY REGION, 2020–2028 (USD MILLION)
    8.4 AMBULATORY CARE CENTERS 
           8.4.1 ENHANCED COLLABORATION BETWEEN HOSPITALS AND AMBULATORY CENTERS TO DRIVE GROWTH
                    TABLE 39 POSITRON EMISSION TOMOGRAPHY MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2020–2028 (USD MILLION)
    8.5 OTHER END USERS 
          TABLE 40 POSITRON EMISSION TOMOGRAPHY MARKET FOR OTHER END USERS, BY REGION, 2020–2028 (USD MILLION)
 
9 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION (Page No. - 91)
    9.1 INTRODUCTION 
          TABLE 41 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2020–2028 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 26 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET SNAPSHOT
          TABLE 42 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
          TABLE 43 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
          TABLE 44 NORTH AMERICA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
          TABLE 45 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
          TABLE 46 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Rising geriatric population to boost growth
                                TABLE 47 US: KEY TARGET DISEASE STATISTICS
                                TABLE 48 US: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 49 US: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Focus on reducing healthcare costs and government investments to drive growth
                                TABLE 50 CANADA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 51 CANADA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
    9.3 EUROPE 
          TABLE 52 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
          TABLE 53 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
          TABLE 54 EUROPE: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
          TABLE 55 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
          TABLE 56 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Increasing prevalence of chronic diseases to boost growth
                                TABLE 57 GERMANY: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 58 GERMANY: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Increasing target patient population to propel growth
                                TABLE 59 FRANCE: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 60 FRANCE: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Government initiatives to support market growth
                                TABLE 61 UK: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 62 UK: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Availability of reimbursement coverage to fuel growth
                                TABLE 63 ITALY: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 64 ITALY: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Increasing prevalence of cancer to drive growth
                                TABLE 65 SPAIN: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 66 SPAIN: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 67 REST OF EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                    TABLE 68 REST OF EUROPE: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
    9.4 ASIA PACIFIC 
          FIGURE 27 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET SNAPSHOT
          TABLE 69 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
          TABLE 70 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
          TABLE 71 ASIA PACIFIC: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
          TABLE 72 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
          TABLE 73 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Healthcare reforms and investments to drive growth
                                TABLE 74 CHINA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 75 CHINA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Fast adoption of advanced technologies to propel growth
                                TABLE 76 JAPAN: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 77 JAPAN: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Improving healthcare infrastructure to drive growth
                                TABLE 78 INDIA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 79 INDIA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Increasing investments in research to provide opportunities for growth
                                TABLE 80 AUSTRALIA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 81 AUSTRALIA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.4.5 SOUTH KOREA
                    9.4.5.1 Presence of advanced healthcare system to drive growth
                                TABLE 82 SOUTH KOREA: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                                TABLE 83 SOUTH KOREA: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
           9.4.6 REST OF ASIA PACIFIC
                    TABLE 84 REST OF ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
                    TABLE 85 REST OF ASIA PACIFIC: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
    9.5 REST OF THE WORLD 
          TABLE 86 REST OF THE WORLD: POSITRON EMISSION TOMOGRAPHY MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
          TABLE 87 REST OF THE WORLD: PET/CT SYSTEMS MARKET, BY TYPE, 2020–2028 (USD MILLION)
          TABLE 88 REST OF THE WORLD: POSITRON EMISSION TOMOGRAPHY MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
          TABLE 89 REST OF THE WORLD: POSITRON EMISSION TOMOGRAPHY MARKET, BY END USER, 2020–2028 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 120)
     10.1 OVERVIEW 
     10.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POSITRON EMISSION TOMOGRAPHY MARKET
     10.3 REVENUE SHARE ANALYSIS 
             FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POSITRON EMISSION TOMOGRAPHY MARKET, 2022
     10.4 MARKET SHARE ANALYSIS 
             FIGURE 29 MARKET SHARE ANALYSIS OF TOP PLAYERS IN PET/CT MARKET, 2022
             TABLE 90 POSITRON EMISSION TOMOGRAPHY MARKET: DEGREE OF COMPETITION
     10.5 COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS (2022) 
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                        FIGURE 30 POSITRON EMISSION TOMOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS, 2022
     10.6 COMPETITIVE BENCHMARKING 
             TABLE 91 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS
             TABLE 92 PRODUCT FOOTPRINT OF COMPANIES
             TABLE 93 REGIONAL FOOTPRINT OF COMPANIES
     10.7 COMPETITIVE SCENARIO AND TRENDS 
             TABLE 94 PRODUCT LAUNCHES
             TABLE 95 DEALS
             TABLE 96 OTHER DEVELOPMENTS
 
11 COMPANY PROFILES (Page No. - 131)
     11.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View)*
             11.1.1 GE HEALTHCARE
                        TABLE 97 GE HEALTHCARE: COMPANY OVERVIEW
                        FIGURE 31 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
             11.1.2 KONINKLIJKE PHILIPS N.V.
                        TABLE 98 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
                        FIGURE 32 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
             11.1.3 SIEMENS HEALTHINEERS
                        TABLE 99 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
                        FIGURE 33 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022)
             11.1.4 SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD
                        TABLE 100 SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD: COMPANY OVERVIEW
             11.1.5 CANON INC.
                        TABLE 101 CANON INC.: COMPANY OVERVIEW
                        FIGURE 34 CANON INC.: COMPANY SNAPSHOT (2022)
             11.1.6 SHIMADZU CORPORATION
                        TABLE 102 SHIMADZU CORPORATION: COMPANY OVERVIEW
                        FIGURE 35 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2021)
             11.1.7 MEDISO LTD.
                        TABLE 103 MEDISO LTD.: COMPANY OVERVIEW
             11.1.8 MINFOUND MEDICAL SYSTEMS CO., LTD
                        TABLE 104 MINFOUND MEDICAL SYSTEMS CO., LTD: COMPANY OVERVIEW
             11.1.9 NEUSOFT CORPORATION
                        TABLE 105 NEUSOFT CORPORATION: COMPANY OVERVIEW
                        FIGURE 36 NEUSOFT CORPORATION: COMPANY SNAPSHOT (2022)
             11.1.10 ONCOVISION
                        TABLE 106 ONCOVISION: COMPANY OVERVIEW
             11.1.11 POSITRON
                        TABLE 107 POSITRON: COMPANY OVERVIEW
             11.1.12 MOLECUBES NV
                        TABLE 108 MOLECUBES NV: COMPANY OVERVIEW
             11.1.13 CMR NAVISCAN
                        TABLE 109 CMR NAVISCAN: COMPANY OVERVIEW
             11.1.14 KINDSWAY BIOTECH
                        TABLE 110 KINDSWAY BIOTECH: COMPANY OVERVIEW
             11.1.15 BRAIN BIOSCIENCES, INC.
                        TABLE 111 BRAIN BIOSCIENCES, INC.: COMPANY OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
     11.2 OTHER PLAYERS 
             11.2.1 SOFIE BIOSCIENCES
             11.2.2 PRESCIENT MEDICAL IMAGING
             11.2.3 REFLEXION
             11.2.4 CUBRESA INC.
             11.2.5 SYNCHROPET, INC.
 
12 APPENDIX (Page No. - 167)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

The study involved four major activities in estimating the current size of the positron emission tomography market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial positron emission tomography market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the positron emission tomography market. The primary sources from the demand side include hospitals, diagnostic imaging centers, and ambulatory care centers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Positron Emission Tomography Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2022, Tier 1 = >USD 50 billion, Tier 2 = USD 1 billion to USD 50 billion, Tier 3 = USD 500 million to USD 1 billion.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the positron emission tomography market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

  • Generating a list of major global players operating in the positron emission tomography market.
  • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/product category)
  • Revenue mapping of major players to cover a major share of the global market share, as of 2022
  • Extrapolating the global value of the positron emission tomography market industry

Positron Emission Tomography Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global positron emission tomography market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the positron emission tomography market was validated using top-down and bottom-up approaches.

Market Definition

Positron emission tomography (PET) refers to the medical imaging technique that is used to visualize metabolic and functional processes in the body. It involves the use of a radioactive tracer, which emits positrons (positively charged particles) as it decays. PET scans help doctors diagnose and monitor a wide range of medical conditions, including cancer, heart disease, and neurological disorders.

Key Stakeholders

  • PET system manufacturers, suppliers, and providers
  • PET software solution providers
  • Private research institutions
  • Private and public hospitals
  • Diagnostic centers
  • Imaging centers
  • Surgical centers
  • Consulting firms

Objectives of the Study

  • To define, describe, and forecast the positron emission tomography market based on product, type, application, enduser, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the revenue of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World
  • To profile the key players and comprehensively analyze their market ranking and core competencies
  • To benchmark players within the market using a proprietary competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of  market share and product footprint

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global positron emission tomography market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to five)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
MD 8683
Published ON
Jun, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Positron Emission Tomography Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback